Christopher Posner, President and CEO of Cara Therapeutics Inc. (NASDAQ:CARA), a small-cap biotech company with a market capitalization of $23.22 million, recently sold shares of the company's common ...

Christopher Posner, President and CEO of Cara Therapeutics, Inc. (NASDAQ:CARA), recently sold 372 shares of the company's common stock. The shares were sold at a price range of $4.72 to $4.74, with ...

Algorhythm Holdings, Inc. (NASDAQ:RIME), a Delaware-incorporated company specializing in phonograph records and prerecorded audio tapes and disks, announced today a significant change to its capital ...

Mullen Automotive Inc. (NASDAQ:MULN), a player in the motor vehicles and passenger car bodies industry, conducted a Special Meeting of Stockholders where key decisions were made regarding the ...

Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR), a Maryland-based real estate investment trust with a market capitalization of $1.8 million, reported adjustments to the conversion price of ...

Angi Inc. (NASDAQ:ANGI), a leading player in the advertising services industry currently trading at $1.84 per share with a market cap of $915 million, has executed significant corporate actions ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company with a market capitalization of $14.83 million, announced today the implementation of a 1-for-16 reverse stock split of its common ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 million, has announced the progression of its Phase 1 clinical trial with ...

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025SOUTH SAN FRANSCISCO, Calif., ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...

H.C. Wainwright maintained a neutral stance on Eyenovia (NASDAQ:EYEN) shares, reiterating a price target of $2.00. The firm's analyst, Matthew Caufield, highlighted the U.S. Food and Drug ...